MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze NBIX →
    • FindStock Picks / Stock Screener
    • Value · NBIXIntrinsic Value Calculator
    • Invest · NBIXInvestment Case
    • Hold · NBIX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NBIX stock logo

NBIX

Neurocrine Biosciences, Inc.

$150.57
-6.02
 (-3.84%)
Exchange:  NASDAQ
Market Cap:  15.241B
Shares Outstanding:  99.5M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Kyle W. Gano
Full Time Employees:  2500
Address: 
6027 Edgewood Bend Court
San Diego
CA
92130
US
Website:  https://www.neurocrine.com
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company’s primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson’s disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
NBNBIX logoNBIXNeurocrine Biosciences, Inc.15.2B21.620.514.3%
BBBBIO logoBBIOBridgeBio Pharma, Inc.14.8B——-23.6%
JAJAZZ logoJAZZJazz Pharmaceuticals plc14.8B64.315.47.2%
EXEXEL logoEXELExelixis, Inc.16.2B18.721.739.7%
ASASND logoASNDAscendis Pharma A/S16.6B16.215.411.4%
BMBMRN logoBMRNBioMarin Pharmaceutical Inc.11.7B—14.5-1.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/02 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,887,1002,355,3002,860,500
Gross Profit1,847,4002,321,3002,808,400
EBITDA416,100639,700666,600
Operating Income250,900570,500619,100
Net Income249,700341,300478,600

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets3,251,4003,718,7004,631,500
Total Liabilities1,019,4001,129,0001,378,400
Total Stockholders Equity2,232,0002,589,7003,253,100
Total Debt428,400455,100415,300
Cash and Cash Equivalents251,100233,000713,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow389,900595,400782,700
Capital Expenditure-28,300-38,200-34,000
Free Cash Flow361,600557,200748,700
Net Income249,700341,300478,600
Net Change in Cash-11,600-18,100480,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,332,277.204Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)5,986,201.666Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)5,524,341Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)1,904,400.361Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)2,194,560.067Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)1,989,623.395Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,346,150.963Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,563,106.565Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,409,873.163Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)2,476,722.697Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)2,780,455.885Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,565,932.005Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)13.750Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)15.250Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)13.130Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)10Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)14Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.355B  ?P/S
 (TTM)
: 
4.12
?Net Income
 (TTM)
: 
341.3M  ?P/E
 (TTM)
: 
21.6
?Enterprise Value
 (TTM)
: 
14.991B  ?EV/FCF
 (TTM)
: 
14.42
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
19.74%  ?ROIC
 (TTM)
: 
14.31%
?Net Debt
 (TTM)
: 
-580.4M  ?Debt/Equity
 (TTM)
: 
0.1
?P/B
 (TTM)
: 
3.94  ?Current Ratio
 (TTM)
: 
2.04

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
20.54Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates NBIX intrinsic value between $169.71 – $262.39 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate NBIX Intrinsic Value

Common questions about NBIX valuation

Is Neurocrine Biosciences, Inc. (NBIX) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Neurocrine Biosciences, Inc. (NBIX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NBIX a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NBIX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NBIX’s P/E ratio?

You can see NBIX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NBIX?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NBIX a good long-term investment?

Whether NBIX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Neurocrine Biosciences, Inc.

  • Neurocrine Biosciences, Inc. intrinsic value calculatorEstimate what the business is worth
  • Neurocrine Biosciences, Inc. 5-year outlookWhat has to go right, and what could go wrong
NBIX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.84
MarketSnap

Trading Metrics:

Open: 156.27   Previous Close: 156.59
Day Low: 150.29   Day High: 158.26
Year Low: 122.14   Year High: 186.12
Price Avg 50: 149.14   Price Avg 200: 149.38
Volume: 1.534M   Average Volume: 1.341M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
09-11-2026 13:46
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
09-11-2026 13:01
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
Neurocrine Biosciences: Breaking Down A Solid Quarter
05-11-2026 04:05
Neurocrine Biosciences: Breaking Down A Solid Quarter
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation
04-11-2026 10:05
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation
Neurocrine Biosciences Q3 Earnings Call Highlights
02-11-2026 21:15
Neurocrine Biosciences Q3 Earnings Call Highlights
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
02-11-2026 21:08
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze NBIX →
    • FindStock Picks / Stock Screener
    • Value · NBIXIntrinsic Value Calculator
    • Invest · NBIXInvestment Case
    • Hold · NBIX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.